FOLH1 and prostate cancer: The aims of our study are (1) to present and describe a single-center consecutive cohort of patients receiving PSMA-RGS due to oligorecurrent prostate cancer and (2) to evaluate the clinical and oncological outcomes of this treatment regarding BFS, TFS and complications.